A primordial obstacle in cardioprotection: the answer resides in our genes.

No abstract is available for this paper.

• Publication year

  2023

• Venue

  Cardiovascular Research

• Publication date

  2023-03-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/cvr/cvad034PMID 36919864
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Signaling Pathways Involved in Myocardial Ischemia–Reperfusion Injury and Cardioprotection: A Systematic Review of Transcriptomic Studies in Sus scrofa

  2022cited by this paper
• Release of humoral cardioprotective triggers but myocardial non-responsiveness to cardioprotection by remote ischemic conditioning in Ossabaw minipigs.

  2022cited by this paper
• Non-responsiveness to cardioprotection by ischaemic preconditioning in Ossabaw minipigs with genetic predisposition to, but without the phenotype of the metabolic syndrome

  2022cited by this paper
• The need for adjusting experimental models to meet clinical reality.

  2022cited by this paper
• Co‐morbidities and co‐medications as confounders of cardioprotection—Does it matter in the clinical setting?

  2020cited by this paper
• Post-Genomic Methodologies and Preclinical Animal Models: Chances for the Translation of Cardioprotection to the Clinic

  2019cited by this paper
• P2Y12 antagonists and cardiac repair post-myocardial infarction: global and regional heart function analysis and molecular assessments in pigs

  2018cited by this paper
• Novel targets and future strategies for acute cardioprotection: Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart

  2017cited by this paper
• Ischaemic conditioning and targeting reperfusion injury: a 30 year voyage of discovery

  2016cited by this paper
• Dual activation of STAT-3 and Akt is required during the trigger phase of ischaemic preconditioning.

  2008cited by this paper

• Recombinant human soluble domain of CD39L3 and ticagrelor: cardioprotective effects in experimental myocardial infarction.

  2024cites this paper
• The IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT): multicenter pig study on the effect of ischemic preconditioning

  2024cites this paper
• Attenuation of ST-segment elevation by ischemic preconditioning: Reflection of cardioprotection in Göttingen but not in Ossabaw minipigs.

  2023cites this paper
• No robust reduction of infarct size and no-reflow by metoprolol pretreatment in adult Göttingen minipigs

  2023cites this paper
• Differences in vasomotor function of mesenteric arteries between Ossabaw minipigs with predisposition to metabolic syndrome and Göttingen minipigs

  2023cites this paper